Debevoise Advises Carlyle in Its Strategic Growth Investment in Saama, Valuing the Company at Up to $430 Million

20 October 2021

Debevoise and Plimpton LLP is advising Carlyle (NASDAQ: CG) in its strategic growth investment and acquisition of a majority stake in Saama, valuing the company at up to $430 million. For more information, please see the company’s press release.

Saama is a leading AI-driven Intelligent Clinical Cloud company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs.

The Debevoise team is led by M&A partner Spencer Gilbert and includes partners Jennifer Chu and Kevin Rinker, counsel Christopher Garrett, David Iozzi, Kim Le and Molly Stockley and associates Aleena Aspervil, Julia Chen, Monisha D’Souza, Hannah Levine, Joel SalomonTiancheng (TC) Huang and Sergio Torres, finance partners Sunil Savkar and Ramya Tiller and associates Marta Poplawski and Adam Silverwood, benefits partners Lawrence Cagney and Meir Katz and associate Zain Kazmi, tax partner Peter Furci and associates Jay Evans and Benjamin Friedman, capital markets associate Benjamin Pedersen, intellectual property partner Henry Lebowitz, FDA regulatory partner Paul Rubin and associate Melissa Runsten and litigation counsel Tricia Sherno..